Reply: "Cannabis Use: A Marker of Clinical Severity in Inflammatory Bowel Disease?"
Inflamm Bowel Dis
.
2023 Nov 2;29(11):e42-e43.
doi: 10.1093/ibd/izad222.
Authors
Danny Glickman
1
,
Shannon Dalessio
2
,
Wesley M Raup-Konsavage
3
,
Kent E Vrana
3
,
Matthew D Coates
2
3
Affiliations
1
Penn State College of Medicine, Hershey, PA, USA.
2
Division of Gastroenterology and Hepatology, Department of Medicine, Penn State College of Medicine, Hershey, PA, USA.
3
Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA.
PMID:
37738640
PMCID:
PMC10628917
(available on
2024-09-21
)
DOI:
10.1093/ibd/izad222
No abstract available
Publication types
Editorial
Research Support, N.I.H., Extramural
Comment
MeSH terms
Cannabinoids*
Cannabis*
Humans
Inflammatory Bowel Diseases*
Longitudinal Studies
Substances
Cannabinoids
Grants and funding
R01 AT012053/AT/NCCIH NIH HHS/United States
R01 DK122364/DK/NIDDK NIH HHS/United States
UL1 TR002014/TR/NCATS NIH HHS/United States